Unlocking the Potential of TIL Therapy in Solid Tumors: A Recap of Turnstone Biologics’ Preclinical Data Presentation at SITC 2023
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Programs Turnstone Biologics, a leading biotechnology company, recently showcased their novel Selected TIL programs designed to selectively expand potent tumor-reactive T cells for the treatment of solid tumors. The data presented at the event further supports the ongoing clinical development of TIDAL-01, Turnstone’s…